Fabrizio Benedetti1, Martina Amanzio, Wilma Thoen. 1. Department of Neuroscience, University of Turin Medical School and National Institute of Neuroscience (INN), Turin, Italy. fabrizio.benedetti@unito.it
Abstract
RATIONALE: Placebos are known to induce analgesia through the activation of μ-opioid receptors in some circumstances, such as after morphine pre-conditioning, an effect that is blocked by opioid antagonists. OBJECTIVES: On the basis of the anti-opioid action of cholecystokinin, here we tested whether the activation of the cholecystokinin type-2 receptors abolishes opioid-induced placebo responses. METHODS: The activation of the cholecystokinin type-2 receptors was performed by means of the agonist pentagastrin, and placebo responses were obtained after morphine pre-conditioning in an experimental human model of pain (tourniquet technique). RESULTS:Opioid-induced placebo responses were completely disrupted by pentagastrin administration. In addition, a high correlation between the response to morphine and the response to placebo was found, and this correlation was completely abolished by pentagastrin. CONCLUSION: These results show that the cholecystokinin-2 receptor agonist, pentagastrin, has the same effect as the μ-opioid receptor antagonist, naloxone, on placebo analgesia induced by morphine pre-conditioning, which suggests that the balance between cholecystokinergic and opioidergic systems is crucial in placebo responsiveness in pain. These findings also suggest that cholecystokinin type-2 receptor hyperactivity might be present in placebo non-responders.
RCT Entities:
RATIONALE: Placebos are known to induce analgesia through the activation of μ-opioid receptors in some circumstances, such as after morphine pre-conditioning, an effect that is blocked by opioid antagonists. OBJECTIVES: On the basis of the anti-opioid action of cholecystokinin, here we tested whether the activation of the cholecystokinin type-2 receptors abolishes opioid-induced placebo responses. METHODS: The activation of the cholecystokinin type-2 receptors was performed by means of the agonist pentagastrin, and placebo responses were obtained after morphine pre-conditioning in an experimental human model of pain (tourniquet technique). RESULTS: Opioid-induced placebo responses were completely disrupted by pentagastrin administration. In addition, a high correlation between the response to morphine and the response to placebo was found, and this correlation was completely abolished by pentagastrin. CONCLUSION: These results show that the cholecystokinin-2 receptor agonist, pentagastrin, has the same effect as the μ-opioid receptor antagonist, naloxone, on placebo analgesia induced by morphine pre-conditioning, which suggests that the balance between cholecystokinergic and opioidergic systems is crucial in placebo responsiveness in pain. These findings also suggest that cholecystokinin type-2 receptor hyperactivity might be present in placebo non-responders.
Authors: Andrea L O Hebb; Jean-François Poulin; Sean P Roach; Robert M Zacharko; Guy Drolet Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2005-10-20 Impact factor: 5.067
Authors: Magne Arve Flaten; Per M Aslaksen; Peter S Lyby; Espen Bjørkedal Journal: Philos Trans R Soc Lond B Biol Sci Date: 2011-06-27 Impact factor: 6.237
Authors: Daniel R Kirkpatrick; Dan M McEntire; Zakary J Hambsch; Mitchell J Kerfeld; Tyler A Smith; Mark D Reisbig; Charles F Youngblood; Devendra K Agrawal Journal: Clin Transl Sci Date: 2015-05-11 Impact factor: 4.689
Authors: Jeremy Howick; Felicity L Bishop; Carl Heneghan; Jane Wolstenholme; Sarah Stevens; F D Richard Hobbs; George Lewith Journal: PLoS One Date: 2013-03-20 Impact factor: 3.240